Researchers shut down a SARS cloaking system: Findings could lead to SARS, MERS vaccines

June 3, 2014 by Elizabeth K. Gardner
Andrew Mesecar, Purdue's Walther Professor of Cancer Structural Biology, works in his lab. Mesecar leads a team of researchers working to develop treatments and vaccines for the SARS and MERS viruses. Credit: Purdue University photo/Steven Yang

A Purdue University-led research team has figured out how to disable a part of the SARS virus responsible for hiding it from the immune system; a critical step in developing a vaccine against the deadly disease.

The findings also have potential applications in the creation of vaccines against other coronaviruses, including MERS, said Andrew Mesecar, who led the research.

"This is a first step toward creating a weakened and safe virus for use in an attenuated live vaccine," said Mesecar, Purdue's Walther Professor of Cancer Structural Biology and professor of biological sciences and chemistry. "This also could serve as a molecular roadmap for performing similar studies on other coronaviruses, like MERS, because this enzyme appears to be common to all viruses within this family."

Mesecar also is a part of a research team studying and creating potential treatment compounds for the Middle East respiratory syndrome coronavirus, or MERS, that recently arrived in the United States. There is currently no treatment or vaccine for the virus, which has an estimated fatality rate of 30 percent, according to the Centers for Disease Control and Prevention.

Because MERS and SARS are related, insight into one could provide a shortcut to finding a treatment or developing a vaccine for the other.

Mesecar and his team captured the molecular structure of a key SARS enzyme, papain-like protease, and revealed how it strips a of the proteins ubiquitin and ISG15, which are involved in triggering an immune response.

A paper detailing the National Institutes of Health and National Institue of Allergy and Infectious Diseases-funded work was published in PLOS Pathogens on May 22 and is available online.

Andrew Mesecar, Purdue's Walther Professor of Cancer Structural Biology, speaks with post-doctoral researcher Yahira M. Baez-Santos (left) in his laboratory. In the background are (from left) graduate student Sakshi Tomar and post-doctoral researcher Sarah E. St. John. Mesecar and his research team study enzymes of the SARS and MERS viruses and create molecules to treat or prevent infection. Credit: Purdue University photo/Steven Yang

"With most viruses, when a cell is infected it sends out an alarm triggering an immune response that fights the infection, but successful viruses are able to trick the ," Mesecar said. "By clipping off these two proteins, SARS short circuits the host cell's signaling pathways and prevents it from alerting the immune system to its presence. By removing these proteins, the enzyme serves as a biological cloaking system for the SARS virus that allows it to live and replicate undetected."

The disruption in its natural signaling pathways also causes an infected cell to miscommunicate with the cells around it, which leads to a response that eventually kills those cells, he said.

"Some treatments prevent a virus from replicating and stop further infection, but that doesn't necessarily prevent a harmful reaction to the virus," Mesecar said. "Sometimes it is the confusion in cellular communication that makes a virus lethal."

The outbreak of SARS, severe acute respiratory syndrome, in 2003 led to hundreds of deaths and thousands of illnesses, and there is currently no treatment. The virus can be transmitted through coughing or sneezing, and the infection can quickly spread from person to person, according to the CDC. SARS spread through two dozen countries over a period of a few months before it was contained. A total of 8,098 people worldwide became ill and 774 died. There have been no reported cases of SARS since 2004.

In 2012 the National Select Agent Registry Program declared SARS virus a select agent, meaning it is considered to have the potential to pose a severe threat to public health and safety.

In addition to hiding the virus from the immune system, the SARS papain-like protease, or PLpro, enzyme also is responsible for snipping the viral polyprotein into individual proteins that are essential for . While some treatments are designed to prevent viral replication, researchers working on a vaccine must retain this function, he said.

"The goal in engineering a SARS virus that could be used as a vaccine is to create one that replicates in cells but is unable to fend off the body's immune response," Mesecar said. "We want enough viral particles to be generated to properly prime the immune sytem to fight off a true infection, but without the virus being able to cause illness in the vaccinated individual."

Mesecar and his team focused on uncovering parts of the SARS PLpro enzyme that would be involved in thwarting the , but which could be altered without affecting viral replication, he said.

The team used X-ray crystallography to solve the three-dimensional structure of the SARS PLpro enzyme in complex with ubiquitin. This enabled them to see how it interatced with the protein and which amino acids are involved in linking the two together. They then used computer models and simulations to determine which amino acids are likely involved in binding ISG15. The researchers mutated the identified so that the SARS PLpro enzyme could no longer interact with the host cell proteins. The team then tested the mutatant enzyme to confirm that it could still perform its role in viral replication.

In addition to Mesecar, co-authors include Purdue postdoctoral researcher Yahira M. Baez-Santos; Kiira Ratia from the University of Illinois, Chicago; and Andrew Kilianski and Susan C. Baker from the Loyola University Chicago Stritch School of Medicine.

Mesecar and his team are currently applying their findings to the MERS virus. They have shown that the MERS PLpro enzyme also removes ISG15 and ubiquitin from host cell proteins, and were able to crystallize the MERS Plpro in complex with ubiquitn and ISG15, he said.

Explore further: First MERS infections detected in Algeria

More information: Structural basis for the ubiquitin-linkage specificity and deISGylating activity of SARS-CoV papain-like protease, PLOS Pathogens, 2014.

Related Stories

First MERS infections detected in Algeria

May 31, 2014
Algeria reported its first two cases of the deadly MERS virus on Saturday, both among pilgrims returning from Saudi Arabia, where most cases and deaths from the disease have been reported.

New experimental vaccine produces immune response against MERS virus

April 30, 2014
The University of Maryland School of Medicine (UM SOM) and Novavax, Inc. today announced that an investigational vaccine candidate developed by Novavax against the recently emerged Middle East Respiratory Syndrome Coronavirus ...

New coronavirus inhibitor exhibits antiviral activity by blocking viral hijacking of host

May 29, 2014
Since the SARS epidemic in 2003, coronaviruses have been on the watch list for emerging pathogens, and the ongoing outbreak of Middle East respiratory syndrome coronavirus (MERS-CoV) confirmed that they represent a serious ...

New MERS death reported in Jordan

June 1, 2014
A 69-year-old man has died in Jordan after being infected with the Middle East Respiratory Syndrome (MERS) coronavirus, a health ministry official said on Sunday.

Saudi death toll from MERS virus rises to 186

May 29, 2014
Saudi Arabia's Health Ministry says 13 people have died over the last two weeks from the Middle Eastern respiratory virus.

Saudis announce two new MERS deaths

May 20, 2014
Saudi Arabia on Tuesday reported two new deaths from the MERS coronavirus, taking to 175 the overall number of fatalities from the respiratory disease in the world's worst-hit country.

Recommended for you

Research examines lung cell turnover as risk factor and target for treatment of influenza pneumonia

July 24, 2017
Influenza is a recurring global health threat that, according to the World Health Organization, is responsible for as many as 500,000 deaths every year, most due to influenza pneumonia, or viral pneumonia. Infection with ...

Scientists propose novel therapy to lessen risk of obesity-linked disease

July 24, 2017
With obesity related illnesses a global pandemic, researchers propose in the Journal of Clinical Investigation using a blood thinner to target molecular drivers of chronic metabolic inflammation in people eating high-fat ...

Raccoon roundworm—a hidden human parasite?

July 24, 2017
The raccoon that topples your trashcan and pillages your garden may leave more than just a mess. More likely than not, it also contaminates your yard with parasites—most notably, raccoon roundworms (Baylisascaris procyonis).

Google searches can be used to track dengue in underdeveloped countries

July 20, 2017
An analytical tool that combines Google search data with government-provided clinical data can quickly and accurately track dengue fever in less-developed countries, according to new research published in PLOS Computational ...

MRSA emerged years before methicillin was even discovered

July 19, 2017
Methicillin resistant Staphylococcus aureus (MRSA) emerged long before the introduction of the antibiotic methicillin into clinical practice, according to a study published in the open access journal Genome Biology. It was ...

New test distinguishes Zika from similar viral infections

July 18, 2017
A new test is the best-to-date in differentiating Zika virus infections from infections caused by similar viruses. The antibody-based assay, developed by researchers at UC Berkeley and Humabs BioMed, a private biotechnology ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.